When is the acquisition expected to close?

The transaction is expected to close later this year, subject to regulatory approvals.

Why is Johnson & Johnson acquiring Firefly Bio?

The acquisition aims to strengthen J&J's oncology pipeline.

What is Johnson & Johnson's stock ticker?

Johnson & Johnson's stock ticker is JNJ.

Johnson & Johnson to Acquire Firefly Bio for $1B to Boost Oncology Pipeline

Johnson & Johnson (JNJ) announced the acquisition of Firefly Bio for $1 billion to strengthen its oncology pipeline. The transaction is expected to close later this year, pending regulatory approvals and customary conditions.

June 9, 2026

1 min read

Source: Pharmaceutical Technology

Key Numbers

deal value

Deal Details

Value: $1 billion.
Acquirer: Johnson & Johnson (JNJ).
Target: Firefly Bio.
Status: Pending, subject to regulatory approvals.

Rationale

J&J aims to enhance its oncology portfolio by leveraging Firefly Bio's innovative technologies. No further details on the rationale were disclosed.

Regulatory Challenges

The deal is subject to standard regulatory approvals, including potential review by CFIUS and antitrust authorities. No specific concerns have been raised yet.

Impact on Stock

The acquisition is expected to have a modest short-term impact on JNJ shares, but investors will watch for long-term growth in the oncology segment.

Frequently Asked Questions

The deal is valued at $1 billion.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.